Generalized multiple cutaneous tumors developed in a 60-year-old Japanese man. Skin biopsy revealed atypical large T lymphocytes infiltrating the dermis. CD30 staining was negative in the tumor cells. The diagnosis of CD30-negative cutaneous large T cell lymphoma was made. Axial and inguinal lymphadenopathy was present, but there was no evidence of bone marrow involvement. Seven cycles of chemotherapy and local electron beam irradiation were administered and complete remission (CR) was attained. As CD30-negative cutaneous large T cell lymphoma has a poor prognosis despite intensive chemotherapy, high-dose chemotherapy followed by CD34 
Primary cutaneous lymphoma (PCL), excluding Sezary syndrome (SS) and mycosis fungoides (MF) which are characterized by epidermotropic infiltrates, designates a heterogeneous group of non-epidermotropic cutaneous lymphomas. 1 Non-epidermotropic PCL has been isolated recently by the European Organization for Research and Treatment of Cancer (EORTC), 2 but optimal treatment has yet to be determined. The presence or absence of CD30 is the determining factor related to the prognosis in the more common types of non-MF PCL of T phenotype. 3, 4 The estimated 5-year survival is 90% for patients with CD30-positive large cell lymphoma vs 15% for those with CD30-negative in the EORTC report. 2 Patients with CD30-negative large T cell lymphoma have been prescribed various regimens from monochemotherapy to intensive chemotherapy or radiation therapy alone or associated with chemotherapy. The relapse rates are high and often fatal. 2, 5, 6 We reported early disseminated recurrence of a patient with CD30-negative large T cell lymphoma and given high-dose chemotherapy followed by unpurged autologous stem cell transplantation (APBSCT). 7 We now describe effective treatment which included high-dose chemotherapy followed by CD34 + -selected autologous peripheral blood stem cell transplantation (CD34 + -APBSCT) in a patient with CD30-negative large T cell lymphoma.
Case report
A 60-year-old Japanese man had detected a nontender cutaneous nodule on his right shoulder in September 1997. Three months later, he noted additional nodules on his trunk, hip, right forearm and left axilla. The size of his nodules gradually enlarged. After 3 months, inguinal lymph node swelling became evident. On admission to the Hospital of Hokkaido University School of Medicine in April 1998, there were multiple cutaneous tumors, some with ulceration, on his right shoulder, trunk, hip, right forearm and left axilla, the size ranging from 5 to 12 cm diameter. Systemic B symptoms were absent and vital signs were normal. Physical examination and CT scan of the chest and abdomen revealed bilateral axial and inguinal lymphadenopathy but no hepatosplenomegaly. There was no evident continuity between skin tumors and lymph nodes. Serum LDH was 799 IU/l but soluble interleukin-2 receptor (sIL2-R) was normal. Serologic studies were negative for human T lymphocytotropic virus-I (HTLV-I) and human immunodeficiency virus (HIV). Bone marrow aspiration and biopsy revealed no involvement by atypical lymphocytes.
Skin biopsy of a tumor on his right shoulder revealed an atypical large lymphocyte infiltration of the entire dermis, without epidermotropism. Immunohistochemical studies showed that the atypical lymphocytes were positive for CD3, UCHL-1, MT-1 and negative for L26, MB-1, CD4, CD8 and CD30. Clonal rearrangement of TCR C␤1 was evident in Southern blot analysis. PCR analysis was not done. Results of axial lymph node biopsy showed diffuse infiltration of atypical lymphoid cells, like those seen in the skin specimen. Clinical and histological findings led to the diagnosis of CD30-negative large T cell lymphoma in the EORTC classification. 2 As the clinical course of CD30-negative large T cell cutaneous lymphoma is aggressive, we prescribed intensive treatment with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (APBSCT), as first-line therapy. 8 Moreover, purging of peripheral blood stem cell (PBSC) with CD34
+ selection was planned from the beginning, because we considered that there was the likelihood of contamination by malignant cells based on our experience and related documentation. 7, 9 The patient was given four cycles of pirarubicin 50 mg/m 2 on day 1 (i.v.), cyclophosphamide 750 mg/m 2 on day 1 (i.v.), vincristine 2 mg on day 1 (i.v.) and prednisolone 50 mg/m 2 on days 1-5 (p.o.) (THP-COP regimen) 10 and a partial clinical remission was achieved. Next, he was given three cycles of etoposide 500 mg/m 2 on day 1 (i.v.), cisplatin 50 mg/m 2 on day 1 (i.v.), ifosphamide 4000 mg/m 2 on day 1 (i.v.) and dexamethasone 16 mg on days 1-3 (i.v.) (VIP regimen). 11 During hematopoietic recovery after the first course of VIP therapy, PBSC were harvested by continuous leukapheresis. Clonal rearrangement of TCR C␤1 in PBSC was not evident in the Southern blot analysis. CD34
+ cells were positively immunoselected as described elsewhere. 12, 13 The overall purity of CD34 + cells was 98.8%. The proportion of CD3 + tumor cells was reduced to 0.38% from 74.0%. The purified CD34
+ cells and CFU-GM numbered 2.2 × 10 6 /kg and 3.2 × 10 5 /kg, respectively. After seven cycles of conventional chemotherapy, residual lymphoma cells were verified in skin biopsies from the tumors on his right shoulder. He was given a total of 30 Gy of involved field electron beam radiotherapy and complete remission was attained. After this therapy, CD34
+ -APBSCT was undertaken. Conditioning prior to APBSCT was with 200 mg/m 2 ranimustine on days −8 and −3, 300 mg/m 2 carboplatin on days −7 to −4, 500 mg/m 2 etoposide on days −6 to −4, and 50 mg/kg cyclophosphamide on days −3 and −2 (MCVC regimen).
14 This conditioning regimen commenced on 24 September 1998, and all purified CD34 + cells were re-infused on day 0. Following CD34 + -APBSCT, the time required for neutrophils to reach over 0.5 × 10 9 /l and platelets to over 5 × 10 9 /l was 8 and 21 days, respectively. On days +21 and +67, low grade fever and mild liver dysfunction occurred, and CMV antigenemia assay showed positive (5/6.6 × 10 4 WBC and 1/2.3 × 10 4 WBC, respectively). 15 Therapy with ganciclovir 10 mg/kg/day for 14 days as well as anti-CMV hyperimmune globulin (5 g/day for 3 days), promptly resolved the symptoms and liver function tests decreased to within normal ranges. He was discharged from hospital on January 1999, and remains in complete remission 16 months after CD34 + -APBSCT. Maintenance chemo-radiotherapy was not prescribed.
Discussion
PCL was initially considered to be a manifestation of systemic lymphoma. Later, based on detailed clinicopathologic studies of well-defined groups of cutaneous lymphomas, it became clear that some types of malignant lymphoma can arise exclusively in the skin and without concurrent extracutaneous disease. 4 These PCL may have a clinical behavior and prognosis differing from those of primary node-based malignant lymphomas of the same histologic subtypes. 16, 17 Two main classification systems are currently used for PCL: the revised European-American classification of lymphoid neoplasms (REAL) 18 and the EORTC classification systems. 2 Although classification of PCL has been established and has become gradually recognized, treatment for patients with PCL has not been well defined, comprising radiotherapy, chemotherapy or both. 5, 6, 17 After these treatments, the poorest prognosis is observed in those with CD30-negative large T cell lymphoma, the 5-year overall survival rate being 15% in the EORTC report. 2 We found three other studies which described clinical features, treatment and prognosis of CD30-negative large T cell lymphoma. 5, 19, 20 Philippe et al 19 retrospectively studied 37 cases of PCL (22 B and 15 T cell phenotype) and nonagressive therapy had been prescribed. They reported that prognosis for PCL was good and comparable for CD30-positive and CD30-negative T cell phenotypes. However, there were only five patients with large cell lymphoma and the others were small and medium cell or immunoblastic type. It is difficult to assess the prognosis of these types of lymphoma from such a small population. Beljaards et al 20 reported clinical features in 18 patients with CD30-negative large T cell lymphoma. Various treatments were given, including polychemotherapy for seven patients and radiotherapy alone for six patients. Eleven patients had a relapse within 1 year, predominantly with skin involvement. Excluding one patient with spontaneous regression, there was only one live patient. Median overall survival was 23 months (range 1 to 56 months). Brice et al 5 reported a multicentric prospective trial of polychemotherapy (LNH 87 protocol) for treatment of the 49 patients with PCL, including 11 with CD30-negative large T cell lymphoma. Despite this aggressive therapy, 10/11 had a relapse with an estimated 5-year survival of 35%. In this report, significant adverse prognostic factors were: histology (CD30-negative large T cell lymphoma) and diffuse cutaneous disease (more than 10% of skin). Event-free survival (EFS) at 5 years was 60% for patients with localized disease vs 20% for those with diffuse disease. Our patient had both adverse prognostic factors. They recommended more intensive regimens or high-dose therapy with autologous stem cell transplantation for patients with CD30-negative large T cell lymphoma.
We reported early and disseminated recurrence of CD30-negative large T cell lymphoma and we treated this patient with high-dose chemotherapy but without total body irradiation (TBI) followed by unpurged APBSCT. 7 In this case, the form of recurrence suggested the strong possibility of contamination of malignant cells in PBSC. Positive selection of CD34 + cells was reported to result in a 1-4 log reduction of tumor cells in apheresis products 21 and a CD34 ؉ -selected APBSC transplantation in CTCL M Nishio et al successful result of this procedure against poor prognosis hematological malignancy has already been reported. 22 Therefore, we prescribed CD34 + -APBSCT. In our patient, PCR analysis was not made but the frequency of CD3 + cells, which was expressed in his tumor cells decreased from 74.0% to 0.38%. Therefore we were convinced that a considerable number of tumor cells in his apheresis products could be purged. We also questioned the need for the TBI-containing conditioning regimen for this lymphoma which had a poor prognosis in the former report. 7 There are reports that conditioning regimens with TBI significantly increase complications of the lung for older patients. 23, 24 For this reason, we preferred the non-TBI regimen.
While it is difficult to determine the necessity and efficacy of CD34 + -APBSCT from such a small number of cases, the contamination of malignant cells in PBSC can contribute to a relapse after APBSCT in patients with a cutaneous lymphoma. Our patient has remained in CR for 16 months. Thus, we consider that CD34
+ -APBSCT is one of the most effective therapies for patients with CD30-negative large T cell lymphoma. The need for TBI remains to be determined.
